Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares opened today at $4.82. Take advantage of ...

Ultragenyx is known for its focus on rare and ultra-rare genetic diseases, often targeting conditions that lack approved ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Shares of ProKidney Corp (NASDAQ: PROK) soared more than 25% in Thursday afternoon trading after the company reported ...

In a report released today, from Citi maintained a Buy rating on ProKidney, with a price target of $9.00. The company’s shares closed yesterday at $3.73. Take advantage of TipRanks Premium at 50% off!

Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...

ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...

Live Updates Live Coverage Updates appear automatically as they are published. Wall Street Moves 9:53 am by Morgan Stanley ...

US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...

Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...

The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.